L. braziliensis NWCL. Such a control group implies not treating infected patients despite the known natural history of L. braziliensis NWCL in this geographical area of South America. Moreover, an explanation of the management of the placebo control patients after the 6month follow-up and of those patients for whom local therapy failed would have been of interest.
Patients were followed for only 6 months. Mucosal leishmaniasis can develop many years after the initial episode of NWCL, so a longer period of time would be needed to conclude the appropriate management for these cases.
Finally, these results, together with those reported by Oliveira-Neto et al [5] , could be misinterpreted, leading to the widespread use of intralesional antimony for L. braziliensis NWCL, assuming there will be a 70% to 80% cure rate. In fact, this approach is suggested by the authors in the discussion for those cases with single lesions.
Clinical trials that compare local and systemic treatments for L. braziliensis NWCL and with a long follow-up period are necessary. In this way all patients would be treated and the risk for mucosal metastases over time following local therapy could be estimated.
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